Neuroendocrine Tumors: a Relevant Clinical Update. Curr Oncol Rep 2022 Jun;24(6):703-714
Date
03/08/2022Pubmed ID
35254612DOI
10.1007/s11912-022-01217-zScopus ID
2-s2.0-85125805464 (requires institutional sign-in at Scopus site) 26 CitationsAbstract
PURPOSE OF REVIEW: The field of neuroendocrine oncology has changed much since the time of Oberndorfer first described and coined the term carcinoid. The purpose of this review is to summarize recent findings and highlight clinically relevant updates in the management of NENs, particularly those that are practice changing.
RECENT FINDINGS: Neuroendocrine tumors (NETs) have replaced carcinoid tumor, for the most part. The classification of neuroendocrine neoplasms (NENs) improved, and the epidemiological understanding of this disease group also expanded with global collaborations and maturation of large tumor registries. Clarity in the utility of some NET biomarkers continues to be evolving. Knowledge of molecular drivers of tumorigenesis increases, and scientific/technological advancements lead the way to multiple drug approvals for the treatment of advanced NETs. The incidence and prevalence of NENs continue to increase, and patients are living longer. Better understanding of molecular drivers and further understanding of the role of immunotherapy in NENs will further elevate the level of care and transform care for all patients with NENs.
Author List
Rizen EN, Phan ATAuthor
Alexandria T. Phan MD Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
HumansImmunotherapy
Incidence
Neuroendocrine Tumors
Registries
